A call to arms: The imperative for antimicrobial stewardship

Clinical Infectious Diseases

Volumn 53, Issue SUPPL. 1, 2011, Pages

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CARBAPENEMASE; COLISTIN; CYTOTOXIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DRUG EFFICACY; DRUG MISUSE; DRUG USE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HEALTH CARE COST; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; HUMANS; KLEBSIELLA PNEUMONIAE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH;

EID: 79960976033     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir362     Document Type: Article

References (28)

1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxinproducing clostridia. N Engl J Med 1978; 298:531-4. (Pubitemid 8295586)
2. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72. (Pubitemid 39179608)
3. Gerding DN. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 2010; 31(Suppl 1):S32-4.
4. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-1. (Pubitemid 41770164)
5. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84. (Pubitemid 41338761)
6. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
7. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
8. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-79.
9. Tschudin-Sutter S, Pargger H, Widmer AF. Hand hygiene in the intensive care unit. Crit Care Med 2010 Aug; 38(Suppl 8):S299-305.
10. Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30:264-72.
11. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-64. (Pubitemid 351269151)
12. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
13. European Centre for Disease Prevention and Control, European Medicines Agency. ECDC/EMEA Joint Technical Report: the bacterial challenge: time to react. Available at: http://www.ecdc.europa.eu/en/publications/Publications/ Forms/ECDC-DispForm.aspx?ID5444. Accessed 27 September 2010.
14. So A, Furlong M, Heddini A. Globalisation and antibiotic resistance. BMJ 2010; 341:c5116.
15. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
16. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005. 2008. JAMA 2010; 304:641-8.
17. Peleg AY, Hooper DC. Hospital-acquired infections due to gramnegative bacteria. N Engl J Med 2010; 362:1804-13.
18. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
19. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54:4971-7.
20. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48:1729-31.
21. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77. (Pubitemid 46084814)
22. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895-903.
23. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010; 51:1074-80.
24. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-7.
25. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010; 54:3271-9.
26. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98. (Pubitemid 37443289)
27. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332:1355.
28. Peltola H, Paakkonen M, Kallio P, Kallio MJ. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 2009; 48:1201-10.